DSIP (delta sleep-inducing peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is a nonapeptide isolated by Monnier et al. in 1977 from the blood of rabbits in which delta wave sleep had been induced by thalamic stimulation. It was the first endogenous sleep-promoting peptide identified. DSIP modulates sleep architecture — specifically increasing slow-wave (delta) sleep — through mechanisms that remain partially characterised but involve HPA axis modulation, CRF antagonism, and possible interaction with opiate systems. It also demonstrates stress-protective and anti-stress properties in animal models, reducing ACTH and corticosterone responses to stressors. Research interest extends to its role in circadian timing, REM/NREM balance, and as a tool for studying endogenous sleep-promoting substances distinct from GABAergic hypnotics.
GHRH interaction: DSIP may potentiate GHRH-induced GH release — linking it to GH secretory control during sleep
Delta wave promotion: EEG studies show increased slow-wave activity (0.5–4 Hz) following DSIP administration — mechanism may involve thalamic gating of cortical oscillations
Opiate system interaction: DSIP shows some properties consistent with opiate receptor interaction — naloxone partially blocks some effects in animal models
BBB penetration: DSIP crosses the blood-brain barrier intact — a key property not shared by many endogenous peptides
The honest picture on DSIP — what the evidence does and does not show
DSIP has a mixed literature. Early studies showed robust delta wave induction in animals and humans; later studies have been less consistent. The receptor has never been cloned. Unlike modern sleep drugs with clearly defined GABA-A or orexin mechanisms, DSIP’s mechanism of action remains partially characterised. This ambiguity makes it scientifically interesting — studying an endogenous sleep peptide with an undefined receptor provides insights into non-GABAergic sleep regulation — but researchers should approach the literature with appropriate critical awareness of replication limitations.
Key Research Studies & Clinical Data
Key DSIP research
Study
Model/Context
Key finding
Monnier et al. 1977 (Experientia)
Rabbit thalamic stimulation → blood transfer
DSIP isolated as first endogenous delta-wave-inducing substance
Graf et al. 1981 (Eur J Pharmacol)
Insomniac patients, IV DSIP
Improved sleep latency and delta wave proportion — human pilot data
Research Protocols — DSIP (Delta Sleep-Inducing Peptide)
Protocol 1: Sleep architecture (rat EEG)
DSIP 30–100 µg/kg SC or ICV in Sprague-Dawley rats. EEG/EMG recording during 6-hour dark phase. Spectral analysis: delta power (0.5–4 Hz), theta (4–8 Hz), sigma (12–16 Hz), NREM duration, REM duration, wake time. Compare vs vehicle and zolpidem positive control.
Protocol 2: HPA axis stress modulation
DSIP 50 µg/kg SC 30 min before restraint stress (60 min) in rats. Plasma ACTH (RIA), corticosterone (ELISA) at 0/30/60/120 min. Hypothalamic CRF mRNA (qPCR). Tests anti-stress HPA mechanism.
Protocol 3: GH secretion link
DSIP 100 µg/kg + GHRH 100 µg/kg vs either alone SC in rats. GH pulse (serial blood draws 0–120 min, ELISA). Tests DSIP + GHRH synergy in GH secretory control during sleep.
Protocol 4: BBB penetration and CNS distribution
DSIP 50 µg/kg IV in rats. Brain region dissection at 30/60/120 min. DSIP quantification by RIA — hippocampus, thalamus, cortex, hypothalamus, brainstem. Confirms CNS distribution pattern.
❓
Frequently Asked Questions
What is DSIP?
DSIP (delta sleep-inducing peptide) is a nonapeptide first isolated in 1977 from rabbit blood during thalamic-stimulated sleep. It increases slow-wave (delta) sleep, modulates the HPA axis (reducing CRF/ACTH/cortisol), and crosses the blood-brain barrier intact.
Does DSIP actually induce sleep?
Early animal and human studies showed DSIP increased delta wave proportion and improved sleep in insomniac subjects. Later replication has been inconsistent. Unlike benzodiazepines or zolpidem (GABA-A mechanism) or suvorexant (orexin antagonism), DSIP’s receptor is not cloned and its mechanism is partially characterised — making it an endogenous sleep biology research tool rather than a characterised pharmacological agent.
How does DSIP differ from other sleep compounds in research?
DSIP is a non-GABAergic, non-orexinergic endogenous sleep-promoting peptide — its mechanism is distinct from all approved sleep drugs. This makes it useful for studying sleep regulation pathways beyond GABA-A and orexin systems. It is also HPA-modulating, unlike most sleep compounds.
What is the HPA axis connection?
DSIP reduces hypothalamic CRF release → reduced pituitary ACTH → reduced adrenal cortisol/corticosterone. This anti-stress effect may be mechanistically linked to its sleep-promoting properties — elevated CRF/cortisol is incompatible with slow-wave sleep. DSIP may improve sleep quality partly by reducing HPA arousal signalling.
What formats does QSC supply DSIP in?
QSC supplies DSIP as lyophilised research vials in 10-vial and 20-vial kits (15mg/vial), ≥99% purity HPLC verified with Janoshik COA. Ships from domestic QSC warehouses in USA, EU, UK, Canada, and Australia.
Research Use Only: All QSC compounds are sold strictly for laboratory research purposes. Not for human use. Not approved by the FDA or equivalent regulatory bodies for human administration. All purchases confirm research intent and compliance with applicable local regulations.
